

HARMONi Phase 3 Clinical Trial

Patients With EGFR+ NSCLC Who Have Progressed
After 3rd Generation EGFR-TKI (osimertinib) / NCT06396065¹


Ivonescimab: Most Advanced PD-1/VEGF Bispecific Antibody
in Clinical Development in the U.S. and EU.*

Brings two validated mechanisms in oncology²⁻⁴ into ONE novel tetravalent molecule.

Ivonescimab simultaneously engages both PD-1 & VEGF

Globally 1,800+ patients have been treated with ivonescimab across Summit and Akeso Inc. clinical trials. Summit is actively recruiting 150 patients in the U.S., Canada and Europe; the overall study will include over 400 patients worldwide.

HARMONi




HARMONi PHASE 3 STUDY DESIGN

Locally advanced or metastatic non-squamous NSCLC:

- Positive sensitive EGFR mutation
- Progressed on 1st/2nd generation EGFR-TKI with negative T790, or on 3rd generation EGFR-TKI
- ECOG = 0 or 1
- Regardless of PD-L1 expression

(N~420)



KEY ELIGIBILITY CRITERIA

- Expected survival ≥3 months
- Locally advanced (Stage IIIB/IIIC) or metastatic (Stage IV) non-squamous NSCLC that has progressed on 3rd generation EGFR-TKI (e.g., osimertinib)
- At least 1 measurable noncerebral per RECIST v1.1 lesion
- Adequate organ and hematologic function
- Prior treatment with one non-EGFR therapy is allowed (i.e. amivantamab, REQORSA, etc.). Prior treatment with immune checkpoint inhibitors, anti-angiogenic therapy and chemotherapy (including ADCs) remain exclusionary
- Tumor does not surround important blood vessels or invade the surrounding vital organs and blood vessels. Lesions with necrosis or cavitation applies only to pulmonary parenchymal lesions (ie, not lymph nodes etc)
- No symptomatic metastases of the central nervous system
- No history of esophageal gastric varices, severe ulcers or wounds that do not heal
- No history of severe bleeding tendencies or coagulopathy, or hemoptysis within last 4 weeks

Ivonescimab is an investigational therapy not approved by any regulatory authority other than China's National Medical Products Administration (NMPA)

*There are no known PD-1-based bispecific antibodies approved by the U.S. Food and Drug Administration ("FDA") or the European Medicines Agency ("EMA").

Abbreviations: ADC=antibody-drug conjugates; DoR=duration of response; ECOG=eastern cooperative oncology group; EGFR=Epidermal growth factor receptor; IRR= independent radiographic review committee; NSCLC=non-small cell lung cancer; PD-1= programmed cell death protein 1; ORR=overall response rate; OS=overall survival; PFS=progression-free survival; TKI=tyrosine kinase inhibitor; Q3W=every 3 weeks; VEGF=vascular endothelial growth factor.

By use of this
QR Code you agree to
Summit's privacy notice
located at smmmtx.com.



Ivonescimab: Designed to Potentially Improve the Balance of Anti-tumor Activity & Safety^{5,6}

Brings two validated mechanisms in oncology²⁻⁴ into ONE novel tetravalent molecule

Cooperative Binding

Potential to drive synergistic anti-tumor activity⁵⁻⁷

Simultaneous blocking of PD-1 & VEGF⁵⁻⁷

Increased Avidity in the Tumor Microenvironment (TME)

VEGF increases affinity to **PD-1 by >18X⁷**


PD-1 increases affinity to **VEGF by >4X⁷**

(*in vitro*)


Enhanced Activity of T Cells

VEGF dimer leads to potential interconnection of ivonescimab molecules, which may increase activity of T cells⁷


(*in vitro*)



Tumor Microenvironment



Tumor Microenvironment with Ivonescimab Cooperative Binding



Images for illustrative purposes only.

For more information contact medinfo@smmmtx.com

1. Phase III Study of AK112 for NSCLC Patients. ClinicalTrials.gov identifier: NCT06396065. <https://clinicaltrials.gov/study/NCT06396065>. (Accessed 2024, May 14); 2. Manegold C, et al. *J Thorac Oncol* 2017;12(2):194-207.; 3. Pardoll, D. *Nat Rev Cancer* 2012;12(4):252-64.; 4. Tamura R, et al. *Med Oncol* 2020;37(1):2.; 5. Zhao Y, et al. *eClinicalMedicine*.2023; 3(62): 102106.; 6. Wang L, et al. *J Thorac Oncol*. 2024 Mar;19(3):465-475.; 7. Zhong T, et al. AACR-NCI-EORTC International Conference 2023. Poster #B123, Abstract #35333, Boston, MA, USA.

Ivonescimab is an investigational therapy that is not approved by any regulatory authority other than China's National Medical Products Administration (NMPA).

SMMTTX.com
medinfo@smmmtx.com

Summit Therapeutics and the Summit Therapeutics logo are trademarks of Summit Therapeutics, Inc. Copyright 2024, Summit Therapeutics, Inc. All Rights Reserved



MAT-SMT112-0060